Literature DB >> 16139182

Central pain in multiple sclerosis--prevalence and clinical characteristics.

A Osterberg1, J Boivie, K-A Thuomas.   

Abstract

Pain is more common in multiple sclerosis (MS) than has previously been recognised. In the present study we have investigated the occurrence of central pain (CP) in MS and defined its characteristics. Questionnaires were sent to all 429 patients with definite MS in the patient register at our neurology department. All admitting to pain were interviewed and offered an extended interview and examination. Three hundred and sixty four patients responded (86%), of whom 57.5% reported pain during the course of their disease (21% nociceptive, 2% peripheral neuropathic and 1% related to spasticity). One hundred patients (27.5%) had CP, including 18 patients (4.9%) with trigeminal neuralgia. The non-trigeminal CP was, in 87%, located in the lower and in 31% in the upper extremities. It was mostly bilateral (76%) and constant, with 88% experiencing daily pain. Only 2% had paroxysmal attacks. Aching, burning, pricking were the commonest qualities. The pain was intense with small to moderate spontaneous variation. In 5.5% of all patients (20% of the patients with CP), pain was a presenting symptom, alone or in combination with other symptoms. The most common neurological symptoms/signs besides CP were sensory abnormalities (98%, dominated by abnormal sensibility to painful stimulus and temperature). Trigeminal neuralgia in MS started later in life and after longer disease duration than non-trigeminal pain. Both types of CP existed either chronically or as a feature of relapse. Central pain is thus an important symptom in MS (around 30%) and causes much suffering.

Entities:  

Mesh:

Year:  2004        PMID: 16139182     DOI: 10.1016/j.ejpain.2004.11.005

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  63 in total

Review 1.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

2.  Abnormal anterior pretectal nucleus activity contributes to central pain syndrome.

Authors:  Peter D Murray; Radi Masri; Asaf Keller
Journal:  J Neurophysiol       Date:  2010-03-31       Impact factor: 2.714

3.  Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.

Authors:  Claudio Solaro; M Cella; Alessio Signori; Vittorio Martinelli; Marta Radaelli; D Centonze; F Sica; M G Grasso; A Clemenzi; S Bonavita; S Esposito; F Patti; E D'Amico; G Cruccu; A Truini
Journal:  J Neurol       Date:  2018-02-05       Impact factor: 4.849

4.  Interdisciplinary treatment of patients with multiple sclerosis and chronic pain: a descriptive study.

Authors:  Amy Burleson Sullivan; Judith Scheman; Anthony Lopresti; Heather Prayor-Patterson
Journal:  Int J MS Care       Date:  2012

5.  Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors:  Weisi Fu; Bradley K Taylor
Journal:  Neurosci Lett       Date:  2015-04-03       Impact factor: 3.046

Review 6.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

Review 7.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

8.  Decreased spinothalamic and dorsal column medial lemniscus-mediated function is associated with neuropathic pain after spinal cord injury.

Authors:  Yenisel Cruz-Almeida; Elizabeth R Felix; Alberto Martinez-Arizala; Eva G Widerström-Noga
Journal:  J Neurotrauma       Date:  2012-08-27       Impact factor: 5.269

Review 9.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Effects of topiramate on dysaesthetic pain in a patient with multiple sclerosis.

Authors:  Antonio Siniscalchi; Luca Gallelli; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.